13. Delirium Screening & Management

Quick Recap

Tier 1 expansion protocol — Neurology System, Protocol 13/13. Cross-cutting supportive-care protocol addressing the single most common form of acute brain dysfunction in the ICU. Complements Post-Cardiac Arrest Syndrome (prior protocol) and should be cross-referenced from every system where mechanically ventilated or critically ill patients are managed, since delirium screening applies universally rather than to one disease category.

1. Definition

Delirium is an acute, fluctuating disturbance of attention, awareness, and cognition that develops over hours to days and is not better explained by a pre-existing or evolving neurocognitive disorder (DSM-5). It is a clinical diagnosis — there is no confirmatory laboratory or imaging test.

Three motoric subtypes:

• Hyperactive: agitation, restlessness, hallucinations, aggression — the most recognized but least common phenotype in the ICU
• Hypoactive: lethargy, inattentiveness, motor slowness — the most common ICU phenotype (accounts for roughly 90% of ICU delirium in major trial populations such as MIND-USA) and the most frequently missed without structured screening
• Mixed: fluctuation between the two

Subsyndromal delirium: patients with some, but not all, features of delirium on a validated screening tool — an intermediate state with its own prognostic significance, now specifically addressed in updated guideline recommendations (Section 21).

Epidemiology: delirium affects 50–75% of mechanically ventilated ICU patients, with roughly 80% of all ICU delirium occurring in patients on mechanical ventilation. It is independently associated with higher mortality, longer duration of mechanical ventilation and hospital stay, higher costs, and a higher risk of long-term cognitive impairment persisting after ICU discharge (post-intensive care syndrome, PICS).

2. Pathophysiology

Delirium's pathophysiology is not fully elucidated but is understood as a final common pathway of aberrant stress responses and neurotransmitter imbalance in a vulnerable brain exposed to precipitating insults:

• Neurotransmitter dysregulation: relative cholinergic deficiency and dopaminergic excess are the classic proposed mechanism, underlying the historical rationale for antipsychotic (dopamine-antagonist) treatment — though this model has been substantially challenged by neutral treatment trial results (Section 22)
• Neuroinflammation: systemic inflammation (sepsis, surgery, critical illness) triggers cytokine-mediated blood-brain barrier disruption and microglial activation
• Circadian and sleep disruption: ICU environments profoundly disrupt melatonin secretion and sleep architecture; this is mechanistically plausible as a contributor, motivating melatonin/circadian-targeted interventions (Section 11), though clinical trial evidence for benefit has been inconsistent (Section 22)
• Impaired cerebral oxidative metabolism: hypoxia, hypotension, and metabolic derangement reduce cerebral oxygen delivery and utilization
• Sedative/analgesic exposure: benzodiazepines in particular are an established, modifiable risk factor; deep sedation of any kind is associated with increased delirium incidence and duration
• Predisposing vs. precipitating factor framework: a vulnerable brain (advanced age, baseline cognitive impairment, frailty, sensory impairment) requires a smaller precipitating insult (infection, metabolic derangement, drugs, immobility, sleep deprivation) to manifest delirium — this framework should guide both risk stratification and modifiable-factor intervention

3. Immediate Stabilization (ABCDE) — Applied to the Newly Delirious Patient

Airway

Breathing

Circulation

Disability

Exposure

Decision point: new delirium is a symptom, not a diagnosis — it always warrants a search for a reversible precipitant (Section 7) before default pharmacologic management is considered.

4. Focused History

• Baseline cognitive status and functional independence (essential for interpreting "acute change")
• Pre-existing dementia, prior delirium episodes, psychiatric history
• Alcohol, benzodiazepine, or opioid use/dependence (withdrawal risk)
• Current medication list, specifically deliriogenic agents (benzodiazepines, anticholinergics, opioids, corticosteroids, antihistamines)
• Sedation depth and duration over the preceding 24–48 hours
• Sleep disruption history during this admission
• Recent surgery, infection, or new organ dysfunction
• Sensory impairment (hearing aids, glasses — often removed/lost in the ICU, itself a modifiable delirium risk factor)
• Family-reported baseline personality/cognition for comparison

5. Comprehensive System-wise Examination

• Neurological: RASS first, then CAM-ICU or ICDSC; formal GCS if depressed consciousness beyond sedation explanation; focal deficit assessment to exclude a structural neurological cause
• Respiratory: hypoxia/hypercapnia assessment
• Cardiovascular: perfusion assessment
• Abdomen: exclude an occult intra-abdominal source of sepsis/inflammation as a precipitant
• Skin/musculoskeletal: assess for withdrawal signs (tremor, diaphoresis, piloerection), pressure injury, restraint-related skin trauma
• Bladder/bowel: urinary retention and constipation are underrecognized, reversible precipitants, particularly in the elderly

POCUS integration: not primary in delirium assessment, but bedside ultrasound may assist in identifying an occult precipitant (e.g., unrecognized effusion, bladder distension) when the cause is not clinically obvious.

6. Syndrome Identification

Delirium itself is the syndrome label once identified; the clinical task is distinguishing it from mimics and identifying its motoric subtype and likely precipitant category:

• Hyperactive vs. hypoactive vs. mixed delirium
• Delirium vs. dementia (acute vs. chronic, fluctuating vs. stable)
• Delirium vs. depression (particularly relevant in hypoactive presentations)
• Delirium vs. non-convulsive status epilepticus (consider EEG if fluctuation pattern is atypical or unresponsive to standard measures)
• Delirium vs. sedative/analgesic oversedation or undersedation
• Delirium vs. withdrawal syndrome (alcohol, benzodiazepine, opioid)

7. Differential Diagnosis (Precipitants to Actively Exclude)

Life-threatening / must-not-miss:

• Hypoxia, hypercapnia
• Hypotension/shock, new sepsis
• Hypoglycemia
• Non-convulsive status epilepticus
• Intracranial catastrophe (hemorrhage, stroke, raised ICP) — especially with any focal deficit or failure to improve
• Severe electrolyte derangement (sodium, calcium)
• Alcohol or benzodiazepine withdrawal (can progress to withdrawal seizures/delirium tremens)

Common causes:

• Infection/sepsis (including occult sources — UTI, line infection)
• Polypharmacy, deliriogenic medications
• Sleep deprivation, immobility, sensory deprivation
• Pain, urinary retention, constipation
• Metabolic derangement (uremia, hepatic dysfunction, thyroid dysfunction)

Drug-induced: benzodiazepines (strongest modifiable association), anticholinergics, opioids (particularly with rapid dose changes), corticosteroids

Iatrogenic: oversedation, understimulation, prolonged immobilization, catheter/line proliferation, restraint use itself

8. Severity Assessment

Richmond Agitation-Sedation Scale (RASS): must be assessed first; delirium tools are only valid at RASS ≥−3.

CAM-ICU (Confusion Assessment Method for the ICU): the most widely validated ICU delirium screening tool. Positive requires: (1) acute onset or fluctuating course, AND (2) inattention, AND either (3) altered level of consciousness OR (4) disorganized thinking.

ICDSC (Intensive Care Delirium Screening Checklist): an 8-item checklist scored over a full nursing shift; score ≥4 indicates delirium. Offers a lower threshold for identifying subsyndromal delirium (score 1–3) compared to the binary CAM-ICU.

Recommended frequency: at least once per nursing shift (minimum every 12 hours), and with any acute change in mental status.

Note on tool selection: both are validated and endorsed by SCCM PADIS; institutional choice typically depends on workflow integration rather than a demonstrated superiority of one over the other.

9. Investigations

Immediate bedside: glucose, SpO2/ABG, vital signs review, RASS + CAM-ICU/ICDSC

Routine labs: electrolytes (sodium, calcium, magnesium, phosphate), renal and hepatic function, CBC (infection screen), TSH if not recently checked

Microbiology: blood cultures and source-directed cultures if new sepsis is suspected as the precipitant

Imaging: CT head is not routinely indicated for delirium alone in the absence of focal neurological signs, head trauma, or failure to improve with standard measures — reserve for a specific clinical trigger to avoid low-yield, resource-intensive imaging

Advanced: EEG if non-convulsive status epilepticus is suspected (atypical fluctuation pattern, unexplained persistent unresponsiveness, prior seizure history)

Repeat frequency: screen at minimum every shift; repeat targeted investigations only if a new precipitant is suspected, not on a fixed schedule

10. Point-of-Care Ultrasound

Not a primary diagnostic modality for delirium itself. Selective use to identify an occult reversible precipitant: bladder ultrasound for urinary retention, lung ultrasound if a new respiratory source of sepsis/hypoxia is suspected, cardiac assessment if a new low-output state is contributing to cerebral hypoperfusion. POCUS should be directed by clinical suspicion of a specific precipitant rather than applied routinely to every delirious patient.

11. Evidence-Based Management

Foundational Framework — The ABCDEF Bundle (SCCM ICU Liberation Bundle)

The single most consistently evidence-supported approach to delirium is bundled, non-pharmacologic prevention, not any pharmacologic agent:

• A — Assess, prevent, and manage pain
• B — Both spontaneous awakening trials (SAT) and spontaneous breathing trials (SBT), paired and coordinated daily
• C — Choice of analgesia and sedation (light sedation targets, dexmedetomidine/propofol preferred over benzodiazepines)
• D — Delirium: assess, prevent, and manage (this protocol)
• E — Early mobility and exercise
• F — Family engagement and empowerment

Bundle compliance is associated with lower mortality, less delirium, and shorter ICU stay in observational data, and operationalizes the evidence below into a single daily workflow.

Non-Pharmacologic Prevention (First-Line, Highest-Certainty Intervention)

• Reorientation (clocks, calendars, natural light exposure, minimizing unnecessary noise/light at night)
• Sleep preservation: cluster care activities, minimize nighttime interruptions, consider earplugs/eye masks
• Early and enhanced mobilization — 2025 PADIS focused update conditionally recommends enhanced mobilization/rehabilitation over usual-care mobilization (moderate certainty) — the strongest-certainty recommendation in the entire updated guideline
• Sensory aid restoration (hearing aids, glasses) as soon as clinically feasible
• Family presence and engagement (the "F" of ABCDEF) — associated with reduced delirium burden in observational data
• Minimize physical restraints where possible — restraints are associated with greater agitation and do not have demonstrated efficacy despite common use to prevent self-extubation/device removal

Sedation Strategy (Directly Modifies Delirium Risk)

• Target light sedation (RASS 0 to −2) unless deep sedation is specifically indicated (e.g., severe ARDS, refractory intracranial hypertension)
• Avoid benzodiazepines where possible — the most consistently identified modifiable pharmacologic risk factor for delirium across observational and trial literature
• 2025 PADIS focused update: dexmedetomidine is conditionally suggested over propofol for mechanically ventilated adults when light sedation and/or delirium reduction are the highest clinical priorities (based on an expanded evidence base of 29 RCTs, up from 3 in the 2018 guideline) — dexmedetomidine may reduce delirium incidence but carries increased bradycardia risk and is not appropriate for patients requiring deep sedation or with hemodynamic instability
• Paired daily sedation interruption + spontaneous breathing trials (the "B" of ABCDEF) reduces delirium burden and ventilator days (cross-reference Post-Extubation Failure & Reintubation protocol, Girard/ABC trial)

Pharmacologic Treatment — Current Evidence Is Substantially More Cautious Than Historical Practice

Antipsychotics (haloperidol, atypical agents):

• Despite being the most commonly used delirium treatment worldwide (haloperidol used by ~65% of surveyed intensivists), the trial evidence base does not support routine use
• MIND-USA (Girard et al., NEJM 2018): 566 delirious ICU patients (89% hypoactive), randomized to haloperidol, ziprasidone, or placebo — no difference in delirium/coma-free days, survival, or length of stay between any group
• AID-ICU (Andersen-Ranberg et al., NEJM 2022): 1000 ICU patients with delirium, haloperidol vs. placebo — no significant difference in the primary outcome (days alive and out of hospital at 90 days)
• However, 1-year follow-up of the AID-ICU cohort (Mortensen et al., Intensive Care Med 2024) found significantly lower 1-year mortality with haloperidol (44.7% vs. 51.6%; adjusted absolute risk difference √6.5%, 95% CI −12.8% to −0.2%) — an intriguing signal independent of the neutral primary delirium outcome, not yet mechanistically explained
• EuRIDICE trial (2023) was stopped early for futility — haloperidol did not increase delirium/coma-free days, though it did reduce concurrent benzodiazepine use
• Updated meta-analysis with trial sequential analysis (2023, 11 RCTs, n=2200): relative risk for mortality with haloperidol vs. placebo 0.89 (96.7% CI 0.77–1.03) — a trend toward benefit that does not reach statistical significance; no difference in delirium/coma-free days (moderate-certainty evidence)
• 2025 PADIS focused update: the task force was unable to issue a recommendation for or against antipsychotics for delirium treatment (conditional, low certainty); explicitly suggests not routinely using haloperidol, an atypical antipsychotic, or a statin to treat delirium, and suggests not using haloperidol/atypical antipsychotics to treat subsyndromal delirium
• Practical synthesis: antipsychotics are not shown to shorten delirium duration and should not be used routinely or prophylactically; a low-dose, time-limited trial remains reasonable for severe agitation posing safety risk to the patient or staff (self-extubation, line removal, violence) where the goal is symptom control rather than delirium resolution — this is a distinct clinical indication from "treating delirium"

Dexmedetomidine for delirium (as distinct from its role in sedation choice above):

• 2025 PADIS conditionally suggests dexmedetomidine for delirium in mechanically ventilated adults where reducing delirium is a priority, reflecting the expanded and more favorable trial base compared to 2018
• Should not be used specifically to prevent delirium in unselected critically ill adults (see prevention section below) — the distinction between treating established delirium/agitation and preventing delirium in a not-yet-delirious patient is an important one that the current guidelines draw explicitly

Melatonin:

• Evidence is genuinely conflicting and has evolved rapidly (30 RCTs available for the 2025 PADIS update vs. 3 in 2018)
• Multiple recent meta-analyses report no significant reduction in delirium incidence: Duan et al. 2023 (OR 0.71, 95% CI 0.46–1.12, p=0.14); Lakbar et al. 2025 (Intensive Care Med, the most rigorous and recent synthesis — primary analysis of 6 low-to-moderate bias RCTs, n=2209, and secondary analysis of 13 RCTs, n=2830, found no significant effect on delirium incidence or mortality)
• A 2023 meta-analysis (Aiello et al.) found no significant effect in the primary analysis (RR 0.76) but a significant reduction in a sensitivity analysis incorporating additional studies (RR 0.67) — illustrating how conclusions shift with inclusion criteria
• 2025 PADIS focused update nonetheless conditionally suggests administering melatonin over no melatonin (low certainty) — this recommendation was based on a broader evidence synthesis including trials comparing melatonin to any comparator (placebo, dexmedetomidine, or benzodiazepines), a different methodology from the Lakbar et al. placebo-focused analysis, which partly explains the discrepant conclusions between the guideline and the most recent dedicated systematic review
• A 2025 low-dose melatonin feasibility trial (0.5 mg vs. 2 mg vs. placebo) confirmed protocol feasibility but was not powered for efficacy
• Practical synthesis: melatonin is low-risk and biologically plausible via circadian/sleep pathways, and guideline bodies have judged the risk-benefit favorable enough for a conditional recommendation, but clinicians should be aware that the most rigorous recent dedicated meta-analysis (Lakbar 2025) found no significant delirium-incidence benefit — this is a genuinely unsettled area, not simply superseded by the latest guideline (see Controversies, Section 23)

Agents specifically NOT recommended for delirium prevention (2025 PADIS, conditional/very low-to-low certainty): haloperidol, atypical antipsychotics, dexmedetomidine, statins, and ketamine are all suggested against for delirium prevention in unselected critically ill adults — this is a distinct recommendation from their (more favorable, in dexmedetomidine's case) role once delirium is established.

Withdrawal-Specific Management

• If alcohol or benzodiazepine withdrawal is identified as the precipitant, manage per a symptom-triggered withdrawal protocol (benzodiazepines remain first-line specifically for withdrawal-related delirium tremens — this is the one clear exception to general benzodiazepine avoidance)

12. Organ Support

• Neurological: no organ-support device per se; the "support" is environmental and pharmacologic as above
• Respiratory: maintain oxygenation/ventilation adequacy as a modifiable delirium precipitant; paired SAT/SBT reduces both ventilator days and delirium burden
• Sedation/analgesia: light-sedation targeting is itself a form of organ (brain) protection in this context
• Nutrition: adequate nutrition supports overall recovery and may indirectly reduce delirium risk via metabolic stability, though direct causal evidence specific to delirium is limited

13. Disease-Specific Therapy

• Melatonin 2–10 mg nightly (dose varies by trial; 2025 PADIS conditionally recommends use, low certainty) — low risk, biologically plausible, efficacy data conflicting (Section 11, 22)
• Dexmedetomidine infusion 0.2–1.4 mcg/kg/hr, titrated to RASS target — preferred over propofol when light sedation/delirium reduction is prioritized; avoid in hemodynamic instability or bradycardia risk
• Haloperidol 2.5–5 mg IV, low-dose and time-limited, reserved for severe agitation posing safety risk rather than as delirium-resolving therapy per se; monitor QTc
• Avoid: routine/prophylactic antipsychotics, routine benzodiazepines (except withdrawal), routine statins or ketamine specifically for delirium prevention

14. Consultation Matrix

15. Monitoring Framework

• Clinical: RASS + CAM-ICU/ICDSC at minimum every nursing shift (q12h), and with any acute mental status change
• Medication review: daily review of sedative/analgesic/deliriogenic drug burden
• Escalation triggers: new focal deficit, persistent unresponsiveness despite sedation holiday, safety-threatening agitation despite non-pharmacologic measures
• De-escalation criteria: two consecutive negative delirium screens → continue routine screening at reduced pharmacologic monitoring intensity; taper any as-needed antipsychotic use as agitation resolves

16. ICU Bundle Checklist (Daily — ABCDEF)

17. Complications

Early:

• Unplanned device removal (self-extubation, line/catheter removal) during hyperactive delirium
• Falls and injury
• Prolonged mechanical ventilation and ICU length of stay
• QTc prolongation / torsades de pointes with antipsychotic use (particularly ziprasidone, and haloperidol at higher doses)

Late:

• Long-term cognitive impairment (a component of post-intensive care syndrome, PICS) — delirium duration is an independent risk factor
• Increased mortality independent of underlying illness severity
• Psychological sequelae (PTSD-like symptoms related to ICU memories, including delirium-related hallucinations)
• Increased caregiver burden post-discharge

Prevention: ABCDEF bundle adherence, minimizing benzodiazepines, early mobilization, sleep preservation

Rescue: structured escalation for safety-threatening agitation (Section 13), search for and treat reversible precipitants before escalating pharmacologic sedation

18. Escalation & De-escalation

Escalation triggers:

• Safety-threatening agitation unresponsive to non-pharmacologic measures → time-limited low-dose antipsychotic or dexmedetomidine trial
• New focal neurological signs → urgent neurological escalation, do not attribute to "delirium" without exclusion of structural causes
• Persistent delirium beyond 5–7 days → multidisciplinary review

De-escalation:

• Taper any antipsychotic used for acute agitation as soon as the safety indication resolves — these are not intended for chronic/routine continuation
• Reduce screening frequency once delirium-free for a sustained period, but do not discontinue entirely for the remainder of the ICU stay in a previously delirious patient

19. ICU Discharge Criteria (Delirium-Relevant Context)

• Delirium resolved or clearly trending toward resolution (negative CAM-ICU/ICDSC on recent consecutive assessments)
• No ongoing safety-threatening agitation
• Any antipsychotic used for acute management tapered/discontinued where clinically appropriate, or a clear plan documented for continuation and follow-up if not
• Cognitive status assessed and communicated to receiving team, with counseling for patient/family regarding expected trajectory of post-ICU cognitive recovery

20. Documentation & Medicolegal Checklist

• RASS and CAM-ICU/ICDSC results documented each shift, not just clinical impression
• Precipitant workup documented when new delirium is identified
• Rationale for any pharmacologic intervention (indication: safety-threatening agitation vs. attempted delirium treatment — these are distinct and should be documented as such given the evidence base)
• QTc monitoring documented if antipsychotics used
• Restraint use: indication, duration, and review documented per institutional policy
• Family communication regarding delirium as a common, usually reversible, but serious ICU complication
• Discharge summary should flag delirium occurrence and duration for continuity of care and cognitive follow-up planning

21. Key Guidelines

• SCCM PADIS 2018 (Devlin et al., Crit Care Med 2018;46:e825-e873): foundational guideline establishing the pain-agitation/sedation-delirium-immobility-sleep framework and the ABCDEF bundle
• SCCM PADIS 2025 Focused Update (Lewis, Balas, Stollings et al., Crit Care Med 2025;53(3):e711-e727): updates and expands the 2018 guideline with five statements on anxiety (new topic), agitation/sedation, delirium, immobility, and sleep disruption; all recommendations conditional. Key updates: dexmedetomidine suggested over propofol for light sedation/delirium reduction priorities (moderate certainty); unable to recommend for/against antipsychotics for delirium treatment (low certainty); explicitly suggests against haloperidol/atypical antipsychotics/dexmedetomidine/statins/ketamine for delirium prevention; suggests melatonin over no melatonin (low certainty); suggests enhanced mobilization/rehabilitation over usual care (moderate certainty)

22. Landmark Trials

23. Controversies

• Melatonin: guideline recommendation vs. best available meta-analytic evidence. The 2025 PADIS focused update conditionally recommends melatonin (low certainty), while the most recent and methodologically rigorous dedicated systematic review (Lakbar et al., 2025, same journal family as ESICM/SCCM literature) found no significant delirium-incidence benefit in either its primary or secondary analysis. The discrepancy substantially reflects differing comparator inclusion (PADIS included trials vs. any comparator, including dexmedetomidine and benzodiazepines, not just placebo) — clinicians should treat this as a genuinely unsettled, low-risk/uncertain-benefit intervention rather than a settled recommendation.
• Antipsychotics for delirium treatment: despite being the most commonly used agents worldwide, MIND-USA and AID-ICU are both neutral on primary delirium outcomes; the AID-ICU 1-year mortality signal is provocative but unexplained and not yet a basis for routine practice change. The 2025 PADIS panel explicitly declined to recommend for or against use — an accurate reflection of genuine equipoise rather than a gap to be filled by expert opinion.
• Dexmedetomidine's dual role: recommended against for delirium prevention but conditionally for delirium treatment/reduction once established — this distinction is easy to blur in practice and merits explicit attention in local protocols to avoid inappropriate prophylactic use.
• CAM-ICU vs. ICDSC: both validated, no clear evidence of superiority of one over the other; institutional workflow, not comparative efficacy data, typically drives selection.
• Role of EEG and biomarker-based delirium detection: promising research area but not yet incorporated into routine screening algorithms; current standard remains validated bedside behavioral tools.
• Restraint use: widespread despite lack of demonstrated efficacy and known association with increased agitation and unplanned device removal — practice significantly outpaces evidence in this area, and this gap is explicitly acknowledged in current guideline documents rather than resolved.

24. References

1. Devlin JW, Skrobik Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46:e825-e873.
2. Lewis K, Balas MC, Stollings JL, et al. A focused update to the clinical practice guidelines for the prevention and management of pain, anxiety, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2025;53(3):e711-e727.
3. Girard TD, Exline MC, Carson SS, et al; MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379(26):2506-2516.
4. Andersen-Ranberg NC, Poulsen LM, Perner A, et al; AID-ICU Trial Group. Haloperidol for the treatment of delirium in ICU patients. N Engl J Med. 2022;387(26):2425-2435.
5. Mortensen CB, Andersen-Ranberg NC, Poulsen LM, et al. Long-term outcomes with haloperidol versus placebo in acutely admitted adult ICU patients with delirium. Intensive Care Med. 2024;50:103-113.
6. Lakbar I, Poole D, Delamarre L, et al. Melatonin and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. Intensive Care Med. 2025. doi:10.1007/s00134-025-08143-1.
7. Duan Y, Yang Y, Zhu W, et al. Melatonin intervention to prevent delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1191830.
8. Aiello G, Cuocina M, La Via L, et al. Melatonin or ramelteon for delirium prevention in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2023;12(2):435.
9. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008;371:126-134.
10. Updated systematic review with meta-analysis and trial sequential analysis: Haloperidol for the treatment of delirium in critically ill patients. [11 RCTs, n=2200] 2023.
11. Schweikert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373:1874-1882.
12. Maclullich AM, Ferguson KJ, Miller T, de Rooij SE, Cunningham C. Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses. J Psychosom Res. 2008.
13. The Washington Manual of Critical Care, 4th ed. 2025 — Delirium chapter (Munoz-Acuna, O'Gara).
14. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant sedation and delirium content.